The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC.~The primary objective will be assessed by the proportion of individuals that provide information on ART use and virological outcomes at the end of the study:~Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up.~Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up.~Secondary objectives:~To evaluate the efficacy of the antiretroviral regimen at week 48 ;~To describe the safety and tolerability of this regimen;~To evaluate adherence across 48 weeks;~To determine the patient satisfaction with this regimen;~To identify individual, social and contextual factors associated with adherence and retention.~The secondary objectives will be evaluated using the following endpoints:~Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;~Frequency, type and severity of adverse events and laboratory abnormalities;~Pill count, analogue visual scale for adherence in each visit;~Changes in the scores of stigma and discrimination scales , quality of life, social support and anxiety and depression (BERGER, WBI,DUKE,CES-D,STAI) at bsl, 4,24, and 48 weeks e;.Changes in the score scales of sexual behaviors, use of drug /alcohol at bsl and at each visit .~f. Through association of baseline individual, social and contextual characteristics with percentage of adherence and retention at 48 weeks.
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).~The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC or 3TC~Secondary objectives:~To evaluate the efficacy of the antiretroviral regimen at week 48 ;~To describe the safety and tolerability of this regimen;~To evaluate adherence across 48 weeks;~To determine the patient satisfaction with this regimen;~To identify individual, social and contextual factors associated with adherence and retention.